Evidence map›Paper›PMID 41136830›Full record

ReviewAdvances in experimental medicine and biology2025

Challenges in the Patent and Legal Environment for Cell Therapies.

Sebastian Sethe

Abstract readReview
PubMed Publisher
In one paragraph

Review in Advances in experimental medicine and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sebastian Sethe, London, UK. SCS@fabuladocet.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Beyond specific regulations relating to manufacturing and safety, broader legal issues accompany the entire 'journey' of a cell therapy product: from procurement of the starting material to efforts of testing and development and operating in a medical marketplace. This chapter charts some legal considerations including the USA, EU, and UK law relating to consent, privacy, preclinical and clinical research, placing on the market, intellectual property protection, and medical commence as they uniquely shape innovation trajectories in cell therapies. These factors need to be considered from the inception of cell therapy and addressed strategically throughout its lifecycle.

Indexed as

Cell- and Tissue-Based TherapyPatents as TopicEuropean UnionHumansInformed ConsentIntellectual PropertyUnited KingdomUnited Statescell therapiesConsentData protectionIntellectual propertyLawLegalMedical tourismPlacing on the marketPrivacyRegulationResearchStem cells

Identifiers

PMID41136830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.